Literature DB >> 22859401

Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.

Anya J Burton1, Richard M Martin, Jenny L Donovan, J Athene Lane, Michael Davis, Freddie C Hamdy, David E Neal, Kate Tilling.   

Abstract

BACKGROUND: Assessment of prostate-specific antigen increase with time (PSA growth) is a fundamental component of active surveillance among men with localized prostate cancer. Factors that influence PSA growth, however, are unclear. We evaluated associations of anthropometric and lifestyle factors with age-related PSA growth.
METHODS: Repeat PSA measures from 404 men, aged 50 to 69 years, with localized prostate cancer undergoing active monitoring were obtained. From log(PSA) measures, age-specific multilevel mixed effect linear models were developed to predict PSA at age 50 years and yearly increase in postdiagnosis PSA. Baseline anthropometric measures, alcohol consumption, occupational class, smoking status, and physical activity were added to the model as covariates.
RESULTS: The median number of repeat PSAs was 13 (range, 2-40), and the mean duration of follow-up was 4.8 years (SD, 2.3). The basic model of age-related PSA growth in men with localized prostate cancer estimated a mean PSA at age 50 of 3.95 ng/mL [95% confidence interval (CI): 3.55 to 4.39] and a yearly increase of 8.50% (95% CI: 7.90% to 9.10%). PSA at age 50 years was 2.1% lower per unit increase in weighted exercise score (95% CI: -3.3 to -0.8), 5.3% lower per 5 cm increase in height (95% CI: -9.4 to -1.1), and 24.5% higher (95% CI: 4.0 to 49.1) in current smokers than never smokers. Similar associations with PSA growth were seen.
CONCLUSION: Smoking and exercise are modifiable lifestyle factors that may be associated with PSA levels in men with localized prostate cancer undergoing active monitoring/surveillance. IMPACT: These factors may be useful in understanding etiology of progression. 2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859401     DOI: 10.1158/1055-9965.EPI-12-0411

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

Review 1.  Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.

Authors:  Stacy Loeb; Sophie M Bruinsma; Joseph Nicholson; Alberto Briganti; Tom Pickles; Yoshiyuki Kakehi; Sigrid V Carlsson; Monique J Roobol
Journal:  Eur Urol       Date:  2014-10-31       Impact factor: 20.096

2.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797

3.  The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts.

Authors:  A D Vandersluis; D E Guy; L H Klotz; N E Fleshner; A Kiss; C Parker; V Venkateswaran
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-06-28       Impact factor: 5.554

4.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

5.  Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?

Authors:  Sean Harrison; Kate Tilling; Emma L Turner; J Athene Lane; Andrew Simpkin; Michael Davis; Jenny Donovan; Freddie C Hamdy; David E Neal; Richard M Martin
Journal:  Cancer Causes Control       Date:  2016-11-09       Impact factor: 2.506

6.  Exercise duRing Active Surveillance for prostatE cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial.

Authors:  Dong-Woo Kang; Adrian S Fairey; Normand G Boulé; Catherine J Field; Kerry S Courneya
Journal:  BMJ Open       Date:  2019-07-04       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.